Skip to Content

Research

PAMELA

Research

Research

Clinicaltrial.gov identifier:
NCT01973660
Status:
Follow-up
Scenario:
Neoadjuvant
Tumour subtype:
HER2+
Phase:
Phase II
Drug/Intervention:
Phenotype by PAM50 as a response predictor

PAM50 HER2-enriched phenotype as a predictor of early response to neoadjuvant lapatinib plus trastuzumab in stage I to IIIA HER2-positive breast cancer

PAM50 HER2-enriched phenotype as a predictor of early response to neoadjuvant lapatinib plus trastuzumab in stage I to IIIA HER2-positive breast cancer.

 

> Download the study protocol

Sponsors

SOLTI

Collaborators

GlaxoSmithKline

Principal investigators

Antonio Llombart, MD, PhD

Director, Servicio de Oncología Médica, Hospital Arnau de Vilanova Valencia

Javier Cortés, MD, PhD

Director, Unidad de Cáncer de mama, Hospital Universitario Vall d’Hebron

Aleix Prat, MD, PhD

Director, Division of Medical Oncology, Hospital Clínic Universitari de Bar

Documents

X
Utilizamos cookies propias y de terceros para mejorar nuestros servicios mediante el análisis de sus hábitos de navegación. Puede cambiar la configuración u obtener más información aquí.